Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases

Neurodegenerative Diseases

Volumn 15, Issue 2, 2015, Pages 63-69

  Fakhoury, Marc ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Blood brain barrier; Central nervous system; Immune system; Inflammation; Neurodegenerative diseases

Indexed keywords

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN DYSFUNCTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FATE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRESS; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNITY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNITY; INFLAMMATION; NEURODEGENERATIVE DISEASES;

EID: 84928938613     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000369933     Document Type: Review

References (50)

1. Cappellano G, et al: Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis 2013; 2: 89-107.
2. Webb AA, Muir GD: The blood-brain barrier and its role in inflammation. J Vet Intern Med 2000; 14: 399-411.
3. Shalev H, Serlin Y, Friedman A: Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009; 2009: 278531.
4. Yan J, Fu Q, Cheng L, Zhai M, Wu W, Huang L, Du G: Inflammatory response in Parkinson's disease (Review). Mol Med Rep 2014; 10: 2223-2233.
5. Jebelli J, Hooper C, Pocock JM: Microglial p53 activation is detrimental to neuronal synapses during activation-induced inflammation: implications for neurodegeneration. Neurosci Lett 2014;583: 92-97.
6. Heneka MT, Kummer MP, Latz E: Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014; 14: 463-477.
7. El Waly B, Macchi M, Cayre M, Durbec P: Oligodendrogenesis in the normal and pathological central nervous system. Front Neurosci 2014; 8: 145.
8. Dheen ST, Kaur C, Ling EA: Microglial activation and its implications in the brain diseases. Curr Med Chem 2007; 14: 1189-1197.
9. Ransohoff RM, Brown MA: Innate immunity in the central nervous system. J Clin Invest 2012; 122: 1164-1171.
10. Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151-170.
11. Iribarren P, Cui YH, Le Y, Wang JM: The role of dendritic cells in neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 2002; 50: 187-196.
12. Miron VE, et al: M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013; 16: 1211-1218.
13. Goverman J: Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393-407.
14. Graber JJ, Ghib-Jalbut S: Protective autoimmunity in nervous system. Pharmacol Ther 2009; 121: 147-159.
15. Luo XG, Chen SD: The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 2012; 1: 9.
16. Larbi A, et al: Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 2009; 17: 91-103.
17. Amor S, et al: Inflammation in neurodegenerative diseases-an update. Immunology 2014; 142: 151-166.
18. Neumann H, Medana IM, Bauer J, Lassmann H: Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25: 313-319.
19. Appel SH: CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest 2009; 119: 13-15.
20. He F, Balling R: The role of regulatory T cells in neurodegenerative diseases. Wiley Interdiscip Rev Syst Biol Med 2013; 5: 153-180.
21. Reynolds AD, et al: Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184: 2261-2271.
22. Beers DR, et al: Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011; 134: 1293-1314.
23. Ding H, Wu F, Nair MP: Image-guided drug delivery to the brain using nanotechnology. Drug Discov Today 2013; 18: 1074-1080.
24. Palmer AM: The role of the blood brain barrier in neurodegenerative disorders and their treatment. J Alzheimers Dis 2011; 24: 643-656.
25. Erickson MA, Banks WA: Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013; 33: 1500-1513.
26. Vos CM, et al: Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005; 20: 953-960.
27. Desai BS, Monahan AJ, Carvey PM, Hendey B: Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 2007; 16: 285-299.
28. Garbuzova-Davis S, et al: Impaired bloodbrain/spinal cord barrier in ALS patients. Brain Res 2012; 1469: 114-128.
29. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP: Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006; 2: 201-211.
30. McCarthy DP, Richards MH, Miller SD: Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Biol 2012; 900: 381-401.
31. Panos M, Christophi GP, Rodriguez M, Scarisbrick IA: Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biol Chem 2014; 395: 1063-1073.
32. Probert L, et al: TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997; 72: 137-141.
33. Haines JD, Inglese M, Casaccia P: Axonal damage in multiple sclerosis. Mt Sinai J Med 2011; 78: 231-243.
34. Brady ST, et al: Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 1999; 19: 7278-7288.
35. Compston A, Coles A: Multiple sclerosis. Lancet 2002; 359: 1221-1231.
36. Trapp BD, Nave KA: Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
37. Weinshenker BG: Epidemiology of multiple sclerosis. Neurol Clin 1996; 14: 291-308.
38. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007; 61: 504-513.
39. Smith KJ, Lassmann H: The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-241.
40. Depino AM, et al: Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003; 18: 2731-2742.
41. Ferrari CC, Tarelli R: Parkinson's disease and systemic inflammation. Parkinsons Dis 2011; 2011: 436813.
42. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Act Neurol Scand 1999; 100: 34-41.
43. Jackson-Lewis V, Blesa J, Przedborski S: Animal models of Parkinson's disease. Parkinsonism Relat Disord 2012; 18(suppl 1):S183-S185.
44. Kadoguchi N, et al: Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease. BMC Neurosci 2014; 15: 79.
45. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342.
46. Hashimoto M, Rockenstein E, Crews L, Masliah E: Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 2003; 4: 21-36.
47. Tuppo EE, Arias HR: The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
48. Sastre M, Klockgether T, Heneka MT: Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006; 24: 167-176.
49. Laurijssens B, Aujard F, Rahman A: Animal models of Alzheimer's disease and drug development. Transl Pharmacol 2013; 10:e319-e327.
50. Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T: Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain Res 2001; 912: 128-136.